420
Participants
Start Date
November 1, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Sintilimab
Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
radiotherapy
Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
Chemotherapy
Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
Sichuan Cancer Hospital and Research Institute, Chengdu
Collaborators (1)
Peking University Cancer Hospital & Institute
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Hebei Medical University Fourth Hospital
OTHER
Anhui Provincial Hospital
OTHER_GOV
The First Affiliated Hospital with Nanjing Medical University
OTHER
Anyang Tumor Hospital
OTHER
Shantou Central Hospital
OTHER
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY
GeneCast Biotechnology Co., Ltd.
INDUSTRY
Sichuan Cancer Hospital and Research Institute
OTHER